GeneDx Holdings (WGS) Enterprise Value (2020 - 2026)

GeneDx Holdings (WGS) has reported Enterprise Value for 7 consecutive years, with -$170.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 7.24% year-over-year to -$170.7 million; the TTM figure through Mar 2026 stood at -$170.7 million (down 7.24% YoY), while the FY2025 annual figure was -$171.3 million, down 21.32% from the prior year.
• Enterprise Value steadied at -$170.7 million in Q1 2026 per WGS's latest filing, from -$171.3 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$106.9 million in Q2 2024 and bottomed at -$315.0 million in Q1 2022.
• Historically, Enterprise Value has averaged -$164.6 million across 5 years, with a median of -$155.1 million in 2025.
• On a YoY basis, Enterprise Value climbed as much as 69.06% in 2022 and fell as far as 973.92% in 2022.
• GeneDx Holdings' Enterprise Value stood at -$123.9 million in 2022, then decreased by 5.01% to -$130.1 million in 2023, then declined by 8.48% to -$141.2 million in 2024, then retreated by 21.32% to -$171.3 million in 2025, then grew by 0.35% to -$170.7 million in 2026.
• Business Quant data shows WGS's Enterprise Value at -$170.7 million in Q1 2026, -$171.3 million in Q4 2025, and -$155.1 million in Q3 2025.